Suvorexant Proof-of-Concept Trial Evaluates Safety, Feasibility for Suicide Risk in MDD
Background
Major Depressive Disorder (MDD) is a debilitating condition, and a significant subset of patients experience elevated suicide risk, representing a critical unmet medical need. Current treatments often fall short in directly addressing acute suicidality or the underlying neurobiological mechanisms contributing to it. The orexin system, particularly orexin-1 and orexin-2 receptors, plays a crucial role in arousal, stress response, and sleep-wake cycles. Dysregulation of this system is implicated in mood disorders and may contribute to the heightened distress and sleep disturbances often seen in individuals with MDD and suicidal ideation, making orexin antagonism a potential therapeutic avenue.
Study Design
This proof-of-concept clinical trial aims to evaluate the initial safety, feasibility, and tolerability of the orexin mixed antagonist suvorexant in veteran adults diagnosed with Major Depressive Disorder and elevated suicide risk. Participants will receive suvorexant 10mg orally every day for the first two weeks, followed by suvorexant 20mg orally every day for the subsequent two weeks, totaling a four-week treatment duration. In-person assessments will occur at week 1, week 3, and week 5, with remote self-report assessments at week 2 and week 4. The primary endpoint is the assessment of safety, feasibility, and tolerability.
Results
This abstract describes the design and objectives of a proof-of-concept clinical trial and does not report any findings or results. The study is currently in the evaluation phase, focusing on establishing the initial safety, feasibility, and tolerability of suvorexant in the target population. Therefore, no specific data, percentages, p-values, or fold-changes are available from this abstract. Secondary objectives include examining potential objectively measured wrist actigraphy as a biological mechanism of clinical improvement and concomitant effects on PTSD-related nightmares using the Pittsburgh Sleep Quality Index-PTSD addendum (PSQI-A). Future publications will detail the outcomes of these assessments.
Key Findings
- Evaluating initial safety of suvorexant in veteran adults with MDD and elevated suicide risk.
- Assessing feasibility of suvorexant administration (10mg then 20mg daily for 4 weeks).
- Determining tolerability of suvorexant in the target population.
- Examining wrist actigraphy as a potential biological mechanism of improvement.
- Evaluating concomitant effects on PTSD-related nightmares using
PSQI-A.
Why It Matters
If successful, this trial could establish a foundation for suvorexant as a novel adjunctive therapy for Major Depressive Disorder patients with elevated suicide risk, potentially offering a new strategy beyond traditional antidepressants. The focus on safety and tolerability is crucial for this vulnerable population, and positive results could pave the way for larger efficacy trials. This research could inform future protocols for targeting the orexin system to mitigate acute suicidality or severe distress, potentially by improving sleep architecture and reducing hyperarousal. While this is an early-stage trial, it highlights the potential for repurposing existing drugs or developing new compounds that modulate the orexin pathway for psychiatric indications, moving towards more targeted interventions for complex mood disorders.
suvorexant
major depressive disorder
suicide risk
orexin antagonist
clinical trial
veterans